{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:04:51Z","timestamp":1773281091849,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Bronchiectasis-chronic obstructive pulmonary disease (COPD) overlap (BCO) is a neglected area of trials, and it is not covered by guidelines for clinical practice. Methods: Using the National Health Insurance Research Database of Taiwan, COPD patients with or without bronchiectasis from 2000 to 2009 were enrolled as the BCO and COPD alone cohorts, respectively. Patients followed for &lt;28 days, diagnosed with COPD who were not prescribed with COPD medications, and those diagnosed with bronchiectasis who did not receive a chest X-ray or computed tomography were excluded. The primary endpoints were acute exacerbations and mortality. Results: There were 831 patients in the BCO cohort and 3321 patients in the COPD alone cohort, covering 3763.08 and 17,348.95 person-years, respectively, from 2000 to 2011. The BCO cohort had higher risk for exacerbations (adjusted hazard ratio (HR) 2.26, 95% confidence interval (CI) 1.94\u20132.63) and mortality (HR 1.46, 95% CI 1.24\u20131.73) than the COPD alone cohort. In the patients overall, the use of statins, macrolides, and mucolytic agents was associated with significantly lower risks of acute exacerbations (statins, HR 0.37, 95% CI 0.29\u20130.46; macrolides, HR 0.65, 95% CI 0.45\u20130.93; mucolytic agents, HR 0.68, 95% CI 0.59\u20130.78). Statins were associated with a significantly lower risk of mortality (HR 0.32, 95% CI 0.25\u20130.41). In the BCO group, statins and mucolytic agents use was associated with significantly lower risks of acute exacerbations (statins, HR 0.44, 95% CI 0.29\u20130.65; mucolytic agents, HR 0.58, 95% CI 0.45\u20130.75). Conclusion: Statins and mucolytic agents use may lower risk of acute exacerbation in patients with BCO.<\/jats:p>","DOI":"10.3390\/jcm7120517","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T11:56:18Z","timestamp":1543924578000},"page":"517","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Mucolytic Agents and Statins Use is Associated with a Lower Risk of Acute Exacerbations in Patients with Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap"],"prefix":"10.3390","volume":"7","author":[{"given":"Vincent Yi-Fong","family":"Su","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Taipei City Hospital Yangming Branch, Taipei 11146, Taiwan"},{"name":"Institute of Clinical Medicine, National Yang-Ming University, Taipei 11221, Taiwan"},{"name":"Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diahn-Warng","family":"Perng","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan"},{"name":"Department of Chest Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Chun","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Department and Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueh-Ching","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Department and Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan"},{"name":"School of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh-Lih","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Department and Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chen","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Department and Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Lin","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Department and Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Chen","family":"Lee","sequence":"additional","affiliation":[{"name":"Department and Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-0232","authenticated-orcid":false,"given":"Tzeng-Ji","family":"Chen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan"},{"name":"Department of Family Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei 11221, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Wei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Chest Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"ref_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (2017, May 15). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available online: https:\/\/goldcopd.org\/gold-2017-global-strategy-diagnosis-management-prevention-copd\/."},{"key":"ref_2","unstructured":"World Health Organization (2018, October 21). The Top 10 Causes of Death. Available online: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1183\/09031936.00170014","article-title":"COPD-bronchiectasis overlap syndrome","volume":"45","author":"Hurst","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1164\/rccm.200305-648OC","article-title":"Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease","volume":"170","author":"Patel","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1164\/rccm.201208-1518OC","article-title":"Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease","volume":"187","author":"Serra","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1503\/cmaj.131547","article-title":"Sleep apnea and risk of pneumonia: A nationwide population-based study","volume":"186","author":"Su","year":"2014","journal-title":"CMAJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.jaip.2018.01.035","article-title":"Use of ICS\/LABA combinations or LAMA is associated with a lower risk of acute exacerbation in patients with coexistent COPD and asthma","volume":"6","author":"Su","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Su, V.Y., Su, W.J., Yen, Y.F., Pan, S.W., Chuang, P.H., Feng, J.Y., Chou, K.T., Yang, K.Y., Lee, Y.C., and Chen, T.J. (2017). Statin use is associated with a lower risk of tuberculosis. Chest.","DOI":"10.1016\/j.chest.2017.04.170"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2352","DOI":"10.1097\/MD.0000000000002352","article-title":"Latent tuberculosis infection and the risk of subsequent cancer","volume":"95","author":"Su","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1378\/chest.10-1758","article-title":"Factors associated with bronchiectasis in patients with COPD","volume":"140","author":"Ballestin","year":"2011","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.hrtlng.2005.04.003","article-title":"Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease?","volume":"35","author":"Gursel","year":"2006","journal-title":"Heart Lung"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/15412555.2014.922174","article-title":"COPD-related bronchiectasis; independent impact on disease course and outcomes","volume":"11","author":"Gatheral","year":"2014","journal-title":"COPD"},{"key":"ref_15","first-page":"CD001287","article-title":"Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease","volume":"7","author":"Poole","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1080\/15412555.2017.1347918","article-title":"Impact of mucolytic agents on COPD exacerbations: A pair-wise and network meta-analysis","volume":"14","author":"Cazzola","year":"2017","journal-title":"COPD"},{"key":"ref_17","first-page":"CD010337","article-title":"Interventions for bronchiectasis: An overview of cochrane systematic reviews","volume":"14","author":"Welsh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_18","first-page":"CD001289","article-title":"Mucolytics for bronchiectasis","volume":"2","author":"Wilkinson","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000195910","article-title":"Role of bromhexine in exacerbations of bronchiectasis. Double-blind randomized multicenter study versus placebo","volume":"58","author":"Olivieri","year":"1991","journal-title":"Respiration"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2174\/1381612043383377","article-title":"Regulatory effects of macrolides on bacterial virulence: Potential role as quorum-sensing inhibitors","volume":"10","author":"Tateda","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.2174\/1381612043383430","article-title":"Immunomodulatory effects of macrolides in the lung: Lessons from in-vitro and in-vivo models","volume":"10","author":"Tsai","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2012-203105","article-title":"Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition","volume":"68","author":"Rogers","year":"2013","journal-title":"Thorax"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","article-title":"Inhibition of proinflammatory cytokine production by pravastatin","volume":"353","author":"Rosenson","year":"1999","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.RES.81.6.963","article-title":"Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin","volume":"81","author":"Dunzendorfer","year":"1997","journal-title":"Circ. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16461","DOI":"10.1038\/srep16461","article-title":"The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: A systematic review and meta-analysis of observational research","volume":"5","author":"Cao","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_27","first-page":"455","article-title":"Atorvastatin as a stable treatment in bronchiectasis: A randomised controlled trial","volume":"2","author":"Mandal","year":"2014","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/7\/12\/517\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:31:12Z","timestamp":1760196672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/7\/12\/517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["jcm7120517"],"URL":"https:\/\/doi.org\/10.3390\/jcm7120517","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,4]]}}}